Efficacy, immunogenicity and safety of the AS04‐HPV‐16/18 vaccine in Chinese women aged 18‐25 years: End‐of‐study results from a phase II/III, randomised, controlled trial

BACKGROUND: Cervical cancer is a major public health concern in China. We report the end‐of‐study results of a phase II/III trial to assess the efficacy, immunogenicity, and safety of the AS04‐human papillomavirus (HPV)‐16/18 vaccine in Chinese women aged 18‐25 years followed for up to 72 months aft...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Zhu, Feng‐Cai, Hu, Shang‐Ying, Hong, Ying, Hu, Yue‐Mei, Zhang, Xun, Zhang, Yi‐Ju, Pan, Qin‐Jing, Zhang, Wen‐Hua, Zhao, Fang‐Hui, Zhang, Cheng‐Fu, Yang, Xiaoping, Yu, Jia‐Xi, Zhu, Jiahong, Zhu, Yejiang, Chen, Feng, Zhang, Qian, Wang, Hong, Wang, Changrong, Bi, Jun, Xue, Shiyin, Shen, Lingling, Zhang, Yan‐Shu, He, Yunkun, Tang, Haiwen, Karkada, Naveen, Suryakiran, Pemmaraju, Bi, Dan, Struyf, Frank
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6797633/
https://ncbi.nlm.nih.gov/pubmed/31305011
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2399
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados